Related Experiment Videos
Response to a hepatitis B polypeptide vaccine in micelle form in a young adult population
Abstract:
Polypeptide micelles with relative molecular weights of 25,000 (p25) and 30,000 (gp30) daltons were prepared from native 22-nm hepatitis B surface antigen (HBsAg) particles. This p25/gp30 complex was alum-adsorbed, and three dosage levels (20 micrograms, 4 micrograms, and 0.8 micrograms) were administered at 0, 1, and 6 months to 51 human volunteers. Local and systemic reactions were clinically insignificant, and all vaccinees seroconverted, regardless of dose. As anticipated, antibody responses diminished as the dosage was reduced. Seroconversion rates and geometric mean antibody levels for the 20 micrograms dosage group were significantly better than those observed with a commercial vaccine and were comparable to those achieved after immunization with 40 micrograms of the intact 22-nm particles used to prepare the polypeptides. By 2 weeks, an anti-HBs response was elicited in 80% of the group receiving 20 micrograms of the polypeptide vaccine. This rapid response to immunization may be particularly beneficial for postexposure prophylaxis where the early development of immunity is advantageous.
Insights
Hepatitis B polypeptide micelles effectively induced immunity in volunteers, with rapid seroconversion observed at the highest dose. This hepatitis B vaccine shows promise for postexposure prophylaxis due to its quick immune response.
Area of Science:
- Immunology
- Vaccinology
- Biochemistry
Background:
- Hepatitis B virus (HBV) poses a significant global health challenge.
- Development of effective and safe HBV vaccines is crucial for prevention.
- Hepatitis B surface antigen (HBsAg) is a key target for vaccine development.
Purpose of the Study:
- To evaluate the immunogenicity and safety of a novel polypeptide micelle vaccine derived from HBsAg.
- To assess the dose-response relationship and speed of antibody development.
- To compare the vaccine's efficacy against a commercial vaccine and intact HBsAg particles.
Main Methods:
- Preparation of polypeptide micelles (p25/gp30) from native 22-nm HBsAg particles.
- Administration of alum-adsorbed polypeptide micelles at three dosage levels to 51 human volunteers.
- Clinical monitoring for local and systemic reactions and serological assessment of anti-HBs antibody responses.
Main Results:
- All vaccinees achieved seroconversion, indicating vaccine efficacy across all tested doses.
- Antibody responses were dose-dependent, with higher doses yielding stronger responses.
- The 20 microgram dose demonstrated superior seroconversion rates and antibody levels compared to a commercial vaccine and was comparable to 40 micrograms of intact HBsAg particles.
- A rapid anti-HBs response (80% seroconversion) was observed within 2 weeks in the 20 microgram group.
Conclusions:
- The HBsAg-derived polypeptide micelle vaccine is safe and immunogenic in humans.
- The vaccine elicits a rapid and robust immune response, particularly at the 20 microgram dosage.
- This rapid response profile makes the vaccine a potential candidate for postexposure prophylaxis of hepatitis B.